Eli Lilly and Co at Wolfe Research Healthcare Conference (Virtual) Transcript
Okay. Thanks for joining us. I'm Tim Anderson, I'm the global large cap biopharma analyst here at Wolfe Research, and it's the second day of our health care conference. And we've been interviewing different members of management from different companies in a fireside chat format. We did 6 of these yesterday. We've got a couple today. The session right now is with Eli Lilly. And we've got 3 different folks. We've got Jake Van Naarden, who's the President of Lilly Oncology, who came to Lilly from the Loxo side when Lilly bought Loxo in 2019. We also have David Hyman, who's Chief Medical Officer of Lilly Oncology, also came from the Loxo side. And on the neuro side, we have Mark Mintun, VP of Lilly Neuroscience R&D. And Mark has been with the company since 2018.
So as you can guess from that background, we're naturally going to talk about 2 disease areas, neuro and oncology. And we're going to start off the discussion today on the neuro side, partly because Mark has to hop off a little bit early.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
